Introduction:Basic information about CAS 303175-44-2|Zapnometinib, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Zapnometinib |
|---|
| CAS Number | 303175-44-2 | Molecular Weight | 409.55 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C13H7ClF2INO2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 2-(2-chloro-4-iodoanilino)-3,4-difluorobenzoic acid |
|---|
| Synonym | More Synonyms |
|---|
Zapnometinib BiologicalActivity
| Description | Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities[1][2][3]. |
|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>Influenza VirusResearch Areas >>CancerSignaling Pathways >>MAPK/ERK Pathway >>MEKResearch Areas >>InfectionSignaling Pathways >>Anti-infection >>Bacterial |
|---|
| Target | MEK:5.7 nM (IC50) |
|---|
| In Vitro | Zapnometinib (0.1 nM-1 μM) inhibits MEK, with IC50s of 30.96 nM, 357 nM, and 15 nM in cell free kinase assay, A549, MDCK cells and human PBMCs[1]. Zapnometinib (100 μM; 4 h) inhibits the Ionomycin (PMA/I)-induced phosphorylation of ERK1/2 in human PBMCs[1]. Zapnometinib (1-100 μM) reduces the viral titers of the IV H1N1pdm09, H3N2[1]. Western Blot Analysis[1] Cell Line: human PBMCs Concentration: 100 μM Incubation Time: 4 h Result: Inhibited the Ionomycin (PMA/I)-increased pERK1/2. |
|---|
| In Vivo | Zapnometinib (8.4-75 mg/kg/day; three times a day p.o.) reduces the lung virus titers and enhances survival of mice after lethal H1N1pdm09 infection[1]. Zapnometinib (150 mg/kg) exhibits AUC values of 860.02 and 1953.68 μg•h/mL in mice by i.v. or oral route, respectively[1]. Animal Model: Female C57BL/6 mice (8 weeks; 21-24 g) were infected with H1N1pdm09[1] Dosage: 8.4, 25, 75 mg/kg/day (2.8, 8.4, 25 mg/kg) Administration: P.o. three times a day Result: Significantly reduced the virus titer at the dose of either 75 mg/kg/day or 25 mg/kg/day. |
|---|
| References | [1]. Laure M, et, al. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. Antiviral Res. 2020 Jun;178:104806. [2]. Hamza H, et, al. Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002. Front Microbiol. 2021 Feb 12;12:611958. [3]. Bruchhagen C, et, al. Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound. Sci Rep. 2018 Jun 14;8(1):9114. |
|---|
Chemical & Physical Properties
| Molecular Formula | C13H7ClF2INO2 |
|---|
| Molecular Weight | 409.55 |
|---|
| Exact Mass | 408.91800 |
|---|
| PSA | 49.33000 |
|---|
| LogP | 4.73760 |
|---|
| InChIKey | XCNBGWKQXRQKSA-UHFFFAOYSA-N |
|---|
| SMILES | O=C(O)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl |
|---|
Synonyms
| 2,8-dimercapto-6-hydroxypurine hydrate,1gr |